China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study of its proprietary drug candidate H1710, a heparanase (HPA) inhibitor, for the treatment of advanced solid tumors.
Drug Profile
H1710 is designed to inhibit the activity and expression of heparanase, an enzyme implicated in tumor progression and metastasis. Preclinical studies have demonstrated that H1710 exhibits significant anti-tumor effects in various animal models, highlighting its potential as a novel therapeutic agent.
Global Significance
Currently, no similar heparanase inhibitor products are approved anywhere in the world. The Phase I study will evaluate H1710’s safety, tolerability, and pharmacokinetics in patients with advanced solid tumors, paving the way for further clinical development.-Fineline Info & Tech
